ENDRA Life Sciences Inc. has announced that it received a letter from The Nasdaq Stock Market LLC on May 27, 2025, indicating non-compliance with the Nasdaq Listing Rule 5550(b)(1). The company's stockholders' equity, reported at $1,752,885 in its recent quarterly report, falls short of the required minimum of $2,500,000 for continued listing on the Nasdaq Capital Market. ENDRA is actively evaluating options to address this deficiency and intends to submit a compliance plan by the July 11, 2025 deadline. The company may be granted until November 23, 2025, to meet the compliance requirements if their plan is accepted. Meanwhile, ENDRA's common stock will continue trading on Nasdaq, but there is no assurance that the compliance plan will be approved or that the company can maintain its listing status.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。